24th EDRN Steering Committee Meeting
March 13-15, 2012
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Agenda

Monday March 12, 2012

6:30 – 8:30 p.m.  Industry Forum
Palm B&C

Tuesday March 13, 2012

7:00 – 8:00 a.m.  Sign-In and Continental Breakfast
Registration Desk/Foyer

8:00 – 8:05 a.m.  Welcome & Introduction
Palm B&C
Joshua LaBaer, M.D., Ph.D., Arizona State University

8:05 – 8:15 a.m.  Opening of Steering Committee Meeting
Palm B&C
Ian Thompson, M.D., University of Texas Health Sciences Center at San Antonio

8:15 – 8:40 a.m.  State of the EDRN
Palm B&C
Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

8:40 a.m. – 12:00 p.m.  Session 1: State of the Art in Proteomics
Palm B&C
Chair: Daniel Liebler, Ph.D., Vanderbilt University School of Medicine
NCI Program Liaison: Jacob Kagan, Ph.D.

8:40 – 9:05 a.m.  Quantitative Biology and Biomarker Discovery without Immunoassays
Steven Carr, Ph.D., Broad Institute

9:05 – 9:15 a.m.  Q&A

9:15 – 9:40 a.m.  Tapping into Glycans for Biomarker Development: New Tools and Applications
Brian Haab, Ph.D., Van Andel Research Institute

9:40 – 9:50 a.m.  Q&A

9:50 – 10:10 a.m.  Break
Tuesday March 13, 2012 Continued

**Session 1: State of the Art in Proteomics Continued**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 – 10:35 a.m.</td>
<td>Unbiased Discovery of Serum Antibody Biomarkers</td>
<td>Thomas Kodadek, Ph.D., Scripps Research Institute</td>
</tr>
<tr>
<td>10:35 – 10:45 a.m.</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>10:45 – 11:00 a.m.</td>
<td>SRM Analysis of Total and Free PSA in Blood</td>
<td>David Camp, Ph.D., Pacific Northwest National Laboratory</td>
</tr>
<tr>
<td>11:00 – 11:05 a.m.</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>11:05 – 11:20 a.m.</td>
<td>Institutional Wisdom: Centralized Informatics for EDRN Comparative Proteomics</td>
<td>David Tabb, Ph.D., Vanderbilt Medical Center</td>
</tr>
<tr>
<td>11:20 – 11:25 a.m.</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>11:25 a.m. – 12:00 p.m.</td>
<td>Panel Discussion led by session chair   [Given the state of science in proteomics and glycomics, what are the most provocative questions the EDRN can address?]</td>
<td></td>
</tr>
</tbody>
</table>

**12:00 – 1:00 p.m.** Lunch (On Your Own)

**1:00 – 3:15 p.m.** Session 2: State of the Art in Genomics

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 – 1:25 p.m.</td>
<td>Deep Sequencing to Uncover Events Supporting Targeted Therapeutics in Individual Patients Diagnosed with Metastatic Triple Negative Breast Cancer</td>
<td>John Carpten, Ph.D., TGen</td>
</tr>
<tr>
<td>1:25 – 1:35 p.m.</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
Tuesday March 13, 2012 Continued

Session 2: State of the Art in Genomics Continued

1:35 – 2:00 p.m. Circulating MicroRNA as Cancer Biomarkers: A Laboratory Medicine Perspective
Palm B&C
Colin Pritchard, M.D., Ph.D., University of Washington

2:00 – 2:10 p.m. Q&A

2:10 – 2:35 p.m. Confidence in Results from State of the Art Genomics Measurements
Marc Salit, Ph.D., National Institute of Standards and Technology

2:35 – 2:45 p.m. Q&A

2:45 – 3:15 p.m. Panel Discussion led by session chair
Given the state of science in genomics, what are the most provocative questions the EDRN can address?

3:15 – 3:35 p.m. Break

3:35 – 5:50 p.m. Session 3: Integrating Imaging and Biomarkers
Palm B&C
Chair: Hemant Roy, M.D., NorthShore University HealthSystem
NCI Program Liaison: Richard Mazurchuk, Ph.D.

3:35 – 4:00 p.m. Probing Tissue Heterogeneity with Multiplex in situ Analysis of Cells and Pathways in Epithelial Tissue
Michael Gerdes, Ph.D., GE Global Research

4:00 – 4:10 p.m. Q&A

4:10 – 4:35 p.m. Clinical Trials of Novel Imaging Biomarkers in ACRIN: Current Status and Future Directions
David Mankoff, M.D., Ph.D., University of Washington

4:35 – 4:45 p.m. Q&A
Tuesday March 13, 2012 Continued

Session 3: Integrating Imaging and Biomarkers Continued

4:45 – 5:10 p.m.  
**Palm B&C**  
**Physiological and Metabolic MR Markers for Characterizing Patients with Cancer**  
Sarah Nelson, Ph.D., University of California, San Francisco

5:10 – 5:20 p.m.  
Q&A

5:20 – 5:50 p.m.  
Panel Discussion led by session chair  
*What are the most provocative questions the EDRN can address on integrating imaging and biomarkers?*

Wednesday March 14, 2012

7:00 – 8:00 a.m.  
Sign-In and Continental Breakfast

8:00 a.m. – 12:00 p.m.  
**Collaborative Group Meetings**

*Palm E*  
Breast and Gynecological Cancers

*Palm F*  
Gastrointestinal Cancers

*Joshua Tree*  
Lung and Upper Aerodigestive Cancers

*Palm B&C*  
Prostate and Urological Cancers

10:00 – 10:20 a.m.  
Break

12:00 – 1:30 p.m.  
Lunch (On Your Own)

12:00 – 1:30 p.m.  
**EDRN EC Meeting (Closed Session)**  
*Dolores Room*

1:30 – 3:30 p.m.  
**Breakout Sessions to Discuss Provocative Questions**

There will be three groups (randomly assigned) and each will discuss questions related to proteomics, genomics and imaging identified during Monday’s Scientific Sessions. EDRN PIs will be assigned to a specific group so that there are PIs from each collaborative group in each discussion group.
24th EDRN Steering Committee Meeting
March 13-15, 2012
Tempe Mission Palms Hotel & Conference Center
Tempe, Arizona

Wednesday March 14, 2012
Breakout Sessions to Discuss Provocative Questions Continued

Palm E
  Discussion Leader Group 1: Sam Hanash, M.D., Ph.D., Fred Hutchinson Cancer Research Center

Palm F
  Discussion Leader Group 2: David Sidransky, M.D., Johns Hopkins University School of Medicine

Palm B&C
  Discussion Leader Group 3: Sanjiv Gambhir, M.D., Ph.D., Stanford University

3:30 – 3:50 p.m. Break

3:50 – 5:50 p.m. Interest Group Meetings
Palm B&C
  Imaging
    Chair: James Brooks M.D., Stanford University
    NCI Liaison: Richard Mazurchuk, Ph.D.

Palm E
  Biomarker Reference Laboratories
    Chair: Daniel Chan, Ph.D., Johns Hopkins University
    NCI Liaison: Lynn Sorbara, Ph.D.

7:00 – 9:00 p.m. Data Sharing and Informatics Subcommittee Meeting

Thursday, March 15, 2012
7:00 – 8:00 a.m. Sign-In and Continental Breakfast
Registration Desk/Foyer

Closed Session EDRN PIs and Co-PIs only
8:00 – 8:20 a.m. Report on Network Consulting Team Meeting
Palm B&C
  Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute
Thursday, March 15, 2012 Continued

8:20 – 9:05 a.m.  Outcome of Provocative Questions Discussions
  *Palm B&C*
  Presentations by three discussion group leaders
  (15 minutes each)

9:05 – 9:15 a.m.  Report from Advocates
  *Palm B&C*

9:15 – 9:30 a.m.  Report from Industry Forum
  Craig Tuttle, M.S., M.B.A., Transgenomic, Inc.
  *Palm B&C*

9:30 – 10:00 a.m.  Outcome of PCA-3 Validation Trial
  John Wei, M.D., University of Michigan
  *Palm B&C*

10:00 – 10:20 a.m.  Break

10:20 – 11:50 a.m.  Team Projects Updates (15 minutes each)
  *Palm B&C*
  - Prostate
  - Breast
  - Ovarian
  - Lung
  - Pancreas
  - Colon

11:50 a.m. – 12:20 p.m.  Reports from Interest Groups (10 minutes each)
  *Palm B&C*
  - BRLs
  - Imaging

12:20 – 12:30 p.m.  Final Remarks
  *Palm B&C*
  - Ian Thompson, M.D., University of Texas Health Sciences Center at San Antonio
  - Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

12:30 p.m.  Adjourn